Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning

Maturitas

Volumn 100, Issue , 2017, Pages 57-63

  Pinkerton, JoAnn V ^a   Bushmakin, Andrew G ^b   Komm, Barry S ^b   Abraham, Lucy ^c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b PFIZER INC   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Conjugated estrogens bazedoxifene; Genitourinary syndrome of menopause; Menopause; MENQOL; Sexual function; Vulvovaginal atrophy

Indexed keywords

BAZEDOXIFENE PLUS CONJUGATED ESTROGEN; BAZEDOXIFENE; INDOLE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACCIDENTAL INJURY; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL EVALUATION; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DYSPAREUNIA; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; INFECTION; INSOMNIA; LEG CRAMP; MAJOR CLINICAL STUDY; MENOPAUSE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE; MIGRAINE; MYALGIA; NAUSEA; PAIN; PERSONAL EXPERIENCE; PHARYNGITIS; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; POSTMENOPAUSE; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SEXUAL FUNCTION; SEXUAL INTERCOURSE; SIDE EFFECT; TREATMENT OUTCOME; VAGINA ATROPHY; VAGINA PAIN; VAGINA PH; VAGINAL DRYNESS; VAGINAL PRURITUS; VAGINITIS; VASODILATATION; ATROPHY; COITUS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PATHOLOGY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; VAGINA; VAGINAL DISEASES; VULVA;

ADULT; AGED; ATROPHY; COITUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MIDDLE AGED; PAIN; POSTMENOPAUSE; PRURITUS; QUALITY OF LIFE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; VAGINA; VAGINAL DISEASES; VULVA;

EID: 85017308431     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2017.03.315     Document Type: Article

References (27)

1. [1] Portman, D.J., Gass, M.L., Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Maturitas 79 (2014), 349–354.
2. [2] Kingsberg, S.A., Wysocki, S., Magnus, L., Krychman, M.L., Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J. Sex. Med. 10 (2013), 1790–1799.
3. [3] Simon, J.A., Kokot-Kierepa, M., Goldstein, J., Nappi, R.E., Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey. Menopause 20 (2013), 1043–1048.
4. [4] Palma, F., Volpe, A., Villa, P., Cagnacci, A., Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: the AGATA study. Maturitas 83 (2016), 40–44.
5. [5] Levine, K.B., Williams, R.E., Hartmann, K.E., Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 15 (2008), 661–666.
6. [6] Semmens, J.P., Tsai, C.C., Semmens, E.C., Loadholt, C.B., Effects of estrogen therapy on vaginal physiology during menopause. Obstet. Gynecol. 66 (1985), 15–18.
7. [7] Duavee [package insert], A Subsidiary of Pfizer Inc. 2015, Wyeth Pharmaceuticals Inc, Philadelphia, PA.
8. [8] Kagan, R., Williams, R.S., Pan, K., Mirkin, S., Pickar, J.H., A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 17 (2010), 281–289.
9. [9] Bachmann, G., Bobula, J., Mirkin, S., Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric 13 (2010), 132–140.
10. [10] Study Evaluating Bazedoxifene/conjugated Estrogen Combinations in Vasomotor Symptoms Associated with Menopause NCT00238732. 2007 < https://clinicaltrials.gov/ct2/show/NCT00238732>, (Accessed 2 May 2016.).
11. [11] Hilditch, J.R., Lewis, J., Peter, A., van Maris, B., Ross, A., Franssen, E., Guyatt, G.H., Norton, P.G., Dunn, E., A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 24 (1996), 161–175.
12. [12] Cappelleri, J.C., Zou, K.H., Bushmakin, A.G., Alvir, J.M.J., Alemayehu, D., Symonds, T., Patient-reported Outcomes. Measurement, Implementation and Interpretation., 2014, CRC Press, Boca Raton, FL.
13. [13] The analysis of variance. Cohen, J., (eds.) Statistical Power Analysis for the Behavioral Sciences, 1988, Lawrence Erlbaum Associates, Hillsdale, NJ, 273–406.
14. [14] Sullivan, G.M., Feinn, R., Using effect size-or why the P value is not enough. J. Grad. Med. Educ. 4 (2012), 279–282.
15. [15] Standardized Beta Coefficient: Definition & Example. 2016 < http://www.statisticshowto.com/standardized-beta-coefficient/>, (Accessed 7 February 2017.).
16. [16] Blumel, J.E., Del, P.M., Aprikian, D., Vallejo, S., Sarra, S., Castelo-Branco, C., Effect of androgens combined with hormone therapy on quality of life in post-menopausal women with sexual dysfunction. Gynecol. Endocrinol. 24 (2008), 691–695.
17. [17] Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dube, R., Cote, I., Labrie, C., Lavoie, L., Berger, L., Gilbert, L., Martel, C., Balser, J., Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 16 (2009), 923–931.
18. [18] Constantine, G., Graham, S., Portman, D.J., Rosen, R.C., Kingsberg, S.A., Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric 18 (2015), 226–232.
19. [19] Fernandes, T., Costa-Paiva, L.H., Pinto-Neto, A.M., Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial. J. Sex. Med. 11 (2014), 1262–1270.
20. [20] Gast, M.J., Freedman, M.A., Vieweg, A.J., de Melo, N.R., Girao, M.J., Zinaman, M.J., A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. Menopause 16 (2009), 247–256.
21. [21] Raghunandan, C., Agrawal, S., Dubey, P., Choudhury, M., Jain, A., A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J. Sex. Med. 7 (2010), 1284–1290.
22. [22] Williams, R.E., Levine, K.B., Kalilani, L., Lewis, J., Clark, R.V., Menopause-specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life. Maturitas 62 (2009), 153–159.
23. [23] Gartoulla, P., Worsley, R., Bell, R.J., Davis, S.R., Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60–65 years. Menopause 22 (2015), 694–701.
24. [24] Laan, E., van Lunsen, R.H., Hormones and sexuality in postmenopausal women: a psychophysiological study. J. Psychosom. Obstet. Gynaecol. 18 (1997), 126–133.
25. [25] van Anders, S.M., Brotto, L., Farrell, J., Yule, M., Associations among physiological and subjective sexual response, sexual desire, and salivary steroid hormones in healthy premenopausal women. J. Sex. Med. 6 (2009), 739–751.
26. [26] van Lunsen, R.H., Laan, E., Genital vascular responsiveness and sexual feelings in midlife women: psychophysiologic, brain, and genital imaging studies. Menopause 11 (2004), 741–748.
27. [27] Basson, R., Leiblum, S., Brotto, L., Derogatis, L., Fourcroy, J., Fugl-Meyer, K., Graziottin, A., Heiman, J.R., Laan, E., Meston, C., Schover, L., van, L.J., Schultz, W.W., Definitions of women's sexual dysfunction reconsidered: advocating expansion and revision. J. Psychosom. Obstet. Gynaecol. 24 (2003), 221–229.